Abstract

CLINICAL TRIALS SUPPORT CORE The Clinical Trials Support Core (CTSC) is a shared resource available to all members of the UICC. It is designed to facilitate execution of high quality clinical cancer investigation. The CTSC enhances interaction among UICC members and provides for easy assembly of multi- departmental teams needed for collaboration on innovative protocols. The CTSC is composed of dedicated staff with expertise in protocol management and study coordination. Administratively, the Director of the CTSC reports to the Associate Director for Clinical Research. The CTSC provides investigators with appropriate routing of protocols through the various internal regulatory committees including the UICC Protocol Review Committee, assists the investigator in protocol modifications and reporting adverse events for ongoing clinical studies, and supplies staff with expertise in data management. The CTSC also participates in posting protocol lists and supporting internal communication about ongoing studies, as well as statistical reporting on accrual. A chargeback system is used to compensate the CTSC of most clinical trials run through the CTSC, however the core also supports innovative, early phase clinical trials for which there is no other source of support.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA086862-02
Application #
6470079
Study Section
Subcommittee E - Prevention &Control (NCI)
Project Start
2001-07-01
Project End
2002-06-30
Budget Start
Budget End
Support Year
2
Fiscal Year
2001
Total Cost
Indirect Cost

  Institution

Name
University of Iowa
Department
Type
DUNS #
041294109
City
Iowa City
State
IA
Country
United States
Zip Code
52242

  Publications

Thompson, Carrie A; Yost, Kathleen J; Maurer, Matthew J et al. (2018) Quality of life at diagnosis predicts overall survival in patients with aggressive lymphoma. Hematol Oncol 36:749-756
Brandt, Kristin E; Falls, Kelly C; Schoenfeld, Joshua D et al. (2018) Corrigendum to: Augmentation of intracellular iron using iron sucrose enhances the toxicity of pharmacological ascorbate in colon cancer cells [Redox Biol. (2018) 82-87]. Redox Biol :
Ding, George X; Alaei, Parham; Curran, Bruce et al. (2018) Image guidance doses delivered during radiotherapy: Quantification, management, and reduction: Report of the AAPM Therapy Physics Committee Task Group 180. Med Phys 45:e84-e99
Wilkes, Justin G; O'Leary, Brianne R; Du, Juan et al. (2018) Pharmacologic ascorbate (P-AscH-) suppresses hypoxia-inducible Factor-1? (HIF-1?) in pancreatic adenocarcinoma. Clin Exp Metastasis 35:37-51
Sweeney, Sean K; Manzar, Gohar S; Zavazava, Nicholas et al. (2018) Tracking embryonic hematopoietic stem cells to the bone marrow: nanoparticle options to evaluate transplantation efficiency. Stem Cell Res Ther 9:204
Alexander, Matthew S; O'Leary, Brianne R; Wilkes, Justin G et al. (2018) Enhanced Pharmacological Ascorbate Oxidation Radiosensitizes Pancreatic Cancer. Radiat Res :
Ghahramani, Grant K; Goetz, Kirsten E; Liu, Vincent (2018) Dermoscopic characterization of cutaneous lymphomas: a pilot survey. Int J Dermatol 57:339-343
Jorgensen, Jeffery B; Smith, Russell B; Coughlin, Andrew et al. (2018) Impact of PET/CT on Staging and Treatment of Advanced Head and Neck Squamous Cell Carcinoma. Otolaryngol Head Neck Surg :194599818794479
Jain, Rohit K; Snyders, Travis; Nandgoapal, Lakshminarayanan et al. (2018) Immunotherapy Advances in Urothelial Carcinoma. Curr Treat Options Oncol 19:79
Guseva, Natalya V; Jaber, Omar; Stence, Aaron A et al. (2018) Simultaneous detection of single-nucleotide variant, deletion/insertion, and fusion in lung and thyroid carcinoma using cytology specimen and an RNA-based next-generation sequencing assay. Cancer Cytopathol 126:158-169

Showing the most recent 10 out of 1080 publications